Dover Advisors LLC Invests $505,000 in Novo Nordisk A/S (NYSE:NVO)

Dover Advisors LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,154 shares of the company’s stock, valued at approximately $505,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. M. Kulyk & Associates LLC increased its stake in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after purchasing an additional 119 shares during the period. Center for Financial Planning Inc. increased its stake in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the period. Tradewinds Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock worth $429,000 after purchasing an additional 124 shares during the period. Exencial Wealth Advisors LLC increased its stake in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock worth $1,987,000 after purchasing an additional 124 shares during the period. Finally, Indie Asset Partners LLC increased its stake in Novo Nordisk A/S by 4.2% during the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock valued at $269,000 after acquiring an additional 126 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the topic of several research reports. Dbs Bank lowered Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday. BMO Capital Markets restated a “market perform” rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Trading Down 1.4%

NVO stock opened at $79.90 on Friday. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The firm has a market cap of $358.57 billion, a P/E ratio of 24.29, a P/E/G ratio of 0.90 and a beta of 0.66. The business’s 50 day moving average is $67.30 and its 200-day moving average is $79.82. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The company had revenue of $11.87 billion for the quarter. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.